BIM-46174
BIM-46174 is a heterotrimeric G protein complex inhibitor. BIM-46174 blocks GPCR downstream signaling by trapping Gα proteins in a nucleotide-free pocket conformation, thereby inhibiting Gαq-mediated calcium release, Gαs-mediated cAMP production, and GPCR-regulated cancer cell invasion. In vitro, BIM-46174 effectively suppresses a variety of clinically multidrug-resistant cell lines and induces tumor cell apoptosis through activation of caspase-3 and PARP cleavage. BIM-46174 also inhibits activation of the Neu1-MMP-9-GPCR signaling platform and downstream NF-κB signaling, and is widely used in the study of cancer signaling pathways and inflammation-related research, including lung cancer, pancreatic cancer, breast cancer, melanoma, and leukemia.
For research use only. We do not sell to patients.
- CAS No.: 195450-11-4
- Formula: C22H30N4OS
- Molecular Weight:398.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
NTR1 0.7 μM (IC50) |
MMP-9 |
MMP-3 |
TLR7 7.94 μM (IC50) |
TLR9 20 μM (IC50) |
Wnt2 |
Caspase 3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MP41 | IC50 |
2.3 μM
Compound: BIM-46174; 4
|
Antiproliferative activity against human MP41 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
Antiproliferative activity against human MP41 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
|
[PMID: 33715360] |
In Vitro
BIM-46174 (1-100 μM; 1 h) in human breast cancer MCF-7 cells, as a heterotrimeric G protein inhibitor, significantly and reversibly blocks cAMP pathway activation mediated by cholera toxin or vasoactive intestinal peptide[1].
BIM-46174 (5-30 μM; 1-24 h) selectively inhibits endothelin-1-coupled intracellular Ca2+ release in melanoma A2058 cells and markedly reverses or abolishes Wnt-2/3a- or neurotensin-induced invasive activity in colorectal cancer HCT8/S11, lung cancer LNM35, and colon cancer HT29 cells (IC50 = 0.7 μM)[1].
BIM-46174 (0.6-30 μM; 72-96 h) exhibits potent in vitro antiproliferative activity across a broad spectrum of human cancer cell lines, with IC50 values ranging from 0.6 to 25 μM, effectively suppresses multiple clinical multidrug-resistant cell lines, and induces apoptosis via Caspase-3 activation and PARP cleavage[1].
BIM-46174 (10-200 μM; 30 min-24 h) in macrophages (RAW-blue/RAW264.7) markedly blocks upstream G protein signaling, thereby inhibiting lmiquimod (HY-B0180)- or nucleic acid-induced TLR7/9 activation and MyD88 adaptor recruitment, resulting in suppression of NF-κB phosphorylation and pro-inflammatory cytokine (TNFα, MCP-1/CCL2) release[2].
BIM-46174 (10-30 μM; 1-30 min) in 3T3-hEGFR cells and human pancreatic cancer cells (PANC-1/MiaPaCa-2) inhibits post-receptor Neu1 sialidase activation induced by epidermal growth factor (EGF) via blockade of upstream G protein signaling, thereby preventing downstream epidermal growth factor receptor (EGFR) autophosphorylation[3].
BIM-46174 (100 μM; 2 h) in human embryonic kidney HEK293 cells strongly inhibits Gαq-dependent intracellular accumulation of the second messenger myo-inositol 1-phosphate (IP1) induced by Carbachol (HY-B1208)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A-427, PC3, HL60, CCRF-CEM, MIA PaCa-2, NCI-H69, U-87MG, A2058, HT29, and DU145 cells
-
Concentration:0.6-25 μM
-
Incubation Time:96 h
-
Result:Inhibited the in vitro proliferation of a large panel of human cancer cell lines, including various anticancer drug-resistant variants, with significantly lower resistance factors than reference drugs.
-
Cell Line:HL60 and NCI-H69 cells
-
Concentration:30 μM
-
Incubation Time:72 h
-
Result:Resulted in a significant 5-fold increase in apoptosis and induced caspase-3 activation along with cleaved PARP appearance.
-
Cell Line:HCT8/S11, LNM35, HT29, and MDCKts.src cells
-
Concentration:5 μM
-
Incubation Time:24h
-
Result:Abrogated or completely reversed the invasive potential induced by Wnt-2, Wnt-3a, neurotensin, or aluminium fluoride, but showed no effect on invasion induced by constitutively activated Gα12, Gα13, or Gβ1γ2 dimers.
-
Cell Line:RAW-blue and RAW264.7 macrophage cells
-
Concentration:20 μM
-
Incubation Time:30 min
-
Result:Inhibited imiquimod- and ODN-induced NF-κB pSer536 activation in the cytoplasmic cell lysates.
-
Cell Line:3T3-hEGFR cells
-
Concentration:20 μM
-
Incubation Time:30 min
-
Result:Inhibited EGF-induced EGFR tyrosine kinase receptor phosphorylation in cell lysates.
In Vivo
BIM-46174 (25 mg/kg; i.p.; twice daily for 8 days) in a human non-small cell lung cancer LNM35 xenograft model significantly reduces tumor growth when combined with Cisplatin (HY-17394) (1 mg/kg, once daily for 5 days) and exhibits good tolerability with low systemic toxicity[1].
BIM-46174 (20 mg/kg; i.p.; twice daily for 5 days) in a human pancreatic cancer MIA PaCa-2 xenograft model significantly delays tumor growth and exhibits synergistic antitumor activity when combined with the topoisomerase inhibitor (HY-13622) while maintaining a favorable safety profile throughout the whole period[1].
BIM-46174 (2 mg/kg/h; continuous intravenous infusion; 6 days) in a rat continuous infusion toxicity model is established as the highest tolerated dose before significant body weight loss, with no marked abnormalities in key biochemical parameters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCLC NCI-H69 tumor xenograft model (Female athymic NCr-nu/nu mice, 4-6 weeks)[1]
-
Dosage:20 or 25 mg/kg
-
Administration:Intraperitoneal injection (i.p.); 25 mg/kg twice daily for 14 days, or 20 mg/kg twice daily for 5 days
-
Result:Showed that administered alone at 25 mg/kg or 20 mg/kg resulted in minimal tumor growth inhibition.
Demonstrated that combined treatment with Cisplatin (HY-17394) (1.5 mg/kg for 5 consecutive days) induced a drastic and significant reduction of the tumor growth rate.
Revealed that combination therapy with the farnesyltransferase inhibitor produced significant antitumor activity.
Observed a limited and acceptable body weight loss across all combination treatment groups, indicating minimal systemic toxicity.
-
Animal Model:NSCLC LNM35 tumor xenograft model (Female athymic NCr-nu/nu mice, 4-6 weeks)[1]
-
Dosage:25 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice daily for 8 days
-
Result:Demonstrated that combined treatment with Cisplatin (HY-17394) (1 mg/kg for 5 consecutive days) achieved a drastic and statistically significant reduction in the tumor growth rate compared to the vehicle or single-agent groups.
Associated with minimal toxicity, presenting only a limited and acceptable body weight loss in the treated animals.
-
Animal Model:Pancreatic cancer MIA PaCa-2 tumor xenograft model (Female athymic NCr-nu/nu mice, 4-6 weeks)[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice daily for 5 days
-
Result:Revealed that combination therapy with the topoisomerase inhibitor (HY-13622) (2 mg/kg twice daily for a 14-day cycle) induced a profound and highly significant delay in the pancreatic tumor growth rate.
Maintained a safe safety profile with minimal toxicity and limited body weight loss observed throughout the regimen.
-
Animal Model:Continuous infusion toxicity evaluation in rats[1]
-
Dosage:2 mg/kg/h
-
Administration:Continuous intravenous infusion for 6 days
-
Result:Established this regimen as the highest tolerable dose before triggering significant body weight loss after 6 days of continuous delivery.
Showed no significant pathopharmacological changes in key biochemical blood markers, including urea, creatinine, glycemia, γ-glutamyl transpeptidase, aspartate aminotransferase, and alanine aminotransferase, indicating no significant liver or kidney dysfunction.
Chemical Information
-
CAS No. 195450-11-4
-
Molecular Weight 398.56
-
Formula C22H30N4OS
-
SMILES
SC[C@H](N)C(N1CCN2C([C@@H]1CC3CCCCC3)=NC(C4=CC=CC=C4)=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Spheroid/Tumor Organoid Invasion Assay
The spheroid/tumor organoid invasion assay measures outward movement of cancer cells from a compact 3D aggregate into an extracellular matrix, usually collagen I, basement membrane matrix, or mixed collagen-Matrigel hydrogels; the readout is generated by bright-field, fluorescence, confocal, or time-lapse imaging of cell egress, invasion area, invasion distance, dispersion, protrusion formation, basement-membrane perforation, or cell trajectories. The assay reflects cell-cell cohesion, cell-matrix adhesion, matrix remodeling, protease-dependent invasion, contractility, and invasion behavior in a 3D microenvironment rather than migration on a flat 2D surface.
-
Ex Vivo Tissue Slice/Explant Invasion Assay
Ex vivo organotypic tissue slice cultures are based on maintaining thin, viable tissue sections at an air-liquid interface to preserve native cytoarchitecture and local cell-matrix interactions, enabling observation of cell behavior such as migration and tissue infiltration within a physiologically relevant 3D microenvironment. The method relies on maintaining tissue viability on porous membrane supports, allowing diffusion of nutrients and oxygen while preserving structural integrity for extended culture periods, which makes it suitable for studying dynamic cellular processes in intact tissue contexts such as cell movement and tissue remodeling. .
-
Patient-Derived Organoid Invasion Assay
Patient-derived organoid (PDO) invasion assays are based on the ability of epithelial tumor organoids to self-organize in three-dimensional extracellular matrix (ECM) hydrogels (commonly Matrigel) and to recapitulate key aspects of in vivo tissue architecture, including polarity, proliferation, and invasive outgrowth when exposed to permissive microenvironmental cues. In this system, invasion is operationally defined as the emergence of multicellular protrusions, collective budding, or single-cell dissemination from the organoid core into the surrounding ECM, reflecting epithelial-mesenchymal plasticity and matrix remodeling capacity. Organoid morphology and invasive behavior are typically monitored using brightfield or confocal microscopy over time, enabling quantitative assessment of invasion area, protrusion number, and structural disruption of the organoid spheroid architecture.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
3D Tumor Spheroid Invasion Assay
3D tumor spheroid invasion assay measures outward tumor-cell movement from a compact multicellular spheroid into a surrounding extracellular matrix, producing image-based readouts such as invasion area, invasion distance, cell dispersion, or time-resolved cell movement. The method models tumor-cell interaction with matrix components in three dimensions and is used to study invasive phenotypes in cancer models including glioblastoma, squamous cell carcinoma, breast cancer, prostate cancer, ovarian cancer, and other solid tumor systems.
-
Matrigel Transwell/Boyden Chamber Invasion Assay
Matrigel Transwell/Boyden chamber invasion assay measures the ability of cells to degrade or traverse an extracellular matrix-coated porous membrane and move from an upper chamber toward a chemoattractant in a lower chamber. Invasion is distinguished from migration by coating the membrane with Matrigel or basement membrane matrix; uncoated inserts measure migration, while coated inserts require cells to cross an ECM barrier before reaching the underside of the membrane.
-
Invadopodia/Fluorescent Gelatin Degradation Assay
Invadopodia/fluorescent gelatin degradation assay detects proteolytic extracellular matrix degradation by cancer-cell invadopodia, which are actin-rich protrusive structures associated with matrix remodeling, invasion, and metastasis. The readout is generated by culturing cells on fluorescent gelatin and measuring dark degraded areas where fluorescent substrate has been locally removed, often together with immunofluorescent detection of invadopodia markers such as F-actin, cortactin, and TKS5.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Calcium Spark Assay
Calcium sparks are localized, transient increases in intracellular calcium concentration ([Ca2+]i) that occur in cardiac myocytes and represent elementary events underlying excitation-contraction coupling. These events are generated by the coordinated opening of clusters of ryanodine receptors (RyRs) on the sarcoplasmic reticulum membrane, leading to a brief release of Ca2+ into the cytosol. The detection and analysis of calcium sparks provide insights into the mechanisms of calcium handling and signaling in cardiac cells. Imaging techniques using fluorescent calcium indicators such as Fluo-3 are employed to visualize these subcellular calcium transients with high spatial and temporal resolution. The protocol is based on established methodologies described in primary literature for both experimental measurement and automated analysis of calcium sparks.
-
Organotypic 3D Invasion Assay
The organotypic 3D invasion assay measures carcinoma-cell invasion into a fibroblast-remodeled extracellular matrix, usually collagen I with or without basement-membrane matrix, under an air-liquid or grid-supported culture condition; the readout is invasion depth, invaded area, or an invasion index from histological or fluorescence images. This assay models stromal regulation of invasion because fibroblasts or CAFs remodel matrix, generate tracks, and can lead collective carcinoma-cell invasion; the resulting cancer-cell penetration into the gel reflects tumor-stroma-ECM interactions rather than migration on a rigid 2D substrate.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Matrigel/ECM Transwell Invasion Assay
The Matrigel/ECM Transwell invasion assay measures the ability of cells to move toward a chemoattractant while crossing an extracellular-matrix barrier placed on a porous membrane; therefore, the readout reflects both chemotactic motility and matrix invasion rather than migration alone. Matrigel is a basement-membrane-rich matrix derived from Engelbreth-Holm-Swarm mouse sarcoma and has been used as a reconstituted basement membrane barrier in chemoinvasion assays. The assay readout is generated by quantifying cells that reach the underside of the insert membrane or lower compartment after incubation, commonly by staining and counting invaded cells or by fluorescence-based quantification.
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
3D Collagen/Hydrogel Matrix Invasion Assay
The 3D collagen/hydrogel matrix invasion assay is based on embedding cells within or on top of a three-dimensional fibrillar extracellular matrix (typically type I collagen or collagen-rich hydrogels) to model cell migration through a physiologically relevant physical barrier. In this system, invasive behavior is quantified by measuring the ability of cells to degrade, remodel, and migrate through the 3D matrix architecture, which better reflects in vivo tissue invasion compared to 2D migration assays. Collagen-based 3D matrices provide structural cues such as fiber alignment and porosity that influence cell motility and integrin-mediated adhesion, enabling observation of collective or single-cell invasion modes depending on matrix density and organization.
Purity & Documentation
References
[1]. Prévost GP, et al. Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. Cancer Res. 2006 Sep 15;66(18):9227-34. [Content Brief]
[2]. Abdulkhalek S, et al. Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses. Cell Signal. 2013 Nov;25(11):2093-105. [Content Brief]
[3]. Gilmour AM, et al. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. Cell Signal. 2013 Dec;25(12):2587-603. [Content Brief]
[4]. Küppers J, et al. Tetrahydroimidazo[1,2-a]pyrazine Derivatives: Synthesis and Evaluation as Gαq -Protein Ligands. Chemistry. 2020 Oct 1;26(55):12615-12623. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- BIM-46174
- 195450-11-4
- BIM46174
- BIM 46174
- Neurotensin Receptor
- MMP
- EGFR
- Toll-like Receptor (TLR)
- Wnt
- Caspase
- PARP
- MyD88
- NF-κB
- TNF Receptor
- Apoptosis
- G protein inhibitor
- GPCR signaling
- Toll-like Receptor
- EGFR signaling
- apoptosis
- HL60 cells
- RAW 264.7 cells
- MCF-7 cells
- A2058 cells
- MIA PaCa-2 cells
- RAG2/Cy double mutant mice
- athymic nude mice
- xenograft model
- lung cancer
- pancreatic cancer
- breast cancer
- Inhibitor
- inhibitor
- inhibit